- Home
- HMR vs CRBP Comparison
HMR vs CRBP Comparison
Compare HMR & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMR
- CRBP
- Stock Information
- Founded
- HMR 1984
- CRBP 2009
- Country
- HMR Greece
- CRBP United States
- Employees
- HMR N/A
- CRBP N/A
- Industry
- HMR Marine Transportation
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- HMR Consumer Discretionary
- CRBP Health Care
- Exchange
- HMR Nasdaq
- CRBP Nasdaq
- Market Cap
- HMR 99.5M
- CRBP 110.3M
- IPO Year
- HMR N/A
- CRBP N/A
- Fundamental
- Price
- HMR $1.55
- CRBP $9.22
- Analyst Decision
- HMR Strong Buy
- CRBP Strong Buy
- Analyst Count
- HMR 2
- CRBP 10
- Target Price
- HMR $6.00
- CRBP $53.22
- AVG Volume (30 Days)
- HMR 87.3K
- CRBP 117.5K
- Earning Date
- HMR 08-11-2025
- CRBP 08-05-2025
- Dividend Yield
- HMR N/A
- CRBP N/A
- EPS Growth
- HMR N/A
- CRBP N/A
- EPS
- HMR N/A
- CRBP N/A
- Revenue
- HMR $27,657,887.00
- CRBP N/A
- Revenue This Year
- HMR $6.54
- CRBP N/A
- Revenue Next Year
- HMR $41.26
- CRBP $270.04
- P/E Ratio
- HMR N/A
- CRBP N/A
- Revenue Growth
- HMR N/A
- CRBP N/A
- 52 Week Low
- HMR $1.45
- CRBP $4.64
- 52 Week High
- HMR $10.04
- CRBP $61.89
- Technical
- Relative Strength Index (RSI)
- HMR N/A
- CRBP 56.77
- Support Level
- HMR N/A
- CRBP $9.10
- Resistance Level
- HMR N/A
- CRBP $9.80
- Average True Range (ATR)
- HMR 0.00
- CRBP 0.55
- MACD
- HMR 0.00
- CRBP -0.00
- Stochastic Oscillator
- HMR 0.00
- CRBP 68.88
About HMR Heidmar Maritime Holdings Corp. Common Stock
Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.